Non-Invasive Blood Glucose Monitoring System Market (By Technology: Spectroscopy, Electromagnetic, Microwave, Ultrasonic, Thermal, Others; By End User: Hospitals, Homecare, Clinics; By Modality: Non wearable, Wearable, Invasive, Non-invasive; By Distribution Channel: Retail sales, Institutional sales) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032

The global Non-Invasive Blood Glucose Monitoring System Market market size was exhibited at USD 22.00 billion in 2022 and is projected to hit around USD 166.05 billion by 2032, growing at a CAGR of 22.4% during the forecast period 2023 to 2032.

Non-Invasive Blood Glucose Monitoring System Market Size 2023 To 2032

Key Takeaways:

  • Based on technology, the spectroscopy segment has captured the highest revenue share in 2022.
  • Based on end users, the home care segment held the highest market share in 2022.
  • Based on modality, the segment of non-wearable maintained a dominating status in the market.
  • Based on modality the segment of the wearable is emerging at a faster rate and it's foreseen to become a larger market from 2023 to 2032.
  • Based on distribution channels, the retail sales segment has emerged as a dominant market.
  • Based on geography, The North America region accounted for the highest revenue share in 2022.

Non-Invasive Blood Glucose Monitoring System Market Market Report Scope

Report Coverage

Details

Market Size in 2023

USD 22.00 Billion

Market Size by 2032

USD 166.05 Billion

Growth Rate From 2023 to 2032

CAGR of 22.4%

Base Year

2022

Forecast Period

2023 to 2032

Segments Covered

By Technology,By End User,By Modality,By Distribution Channel

Market Analysis (Terms Used)

Value (US$ Million/Billion) or (Volume/Units)

Regional Scope

North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa

Key Companies Profiled

Abbott Laboratories ,Medtronic plc, F. Hoffmann-La Roche Ltd., Ascensia Diabetes Care ,Dexcom, Inc., Sanofi Novo Nordisk ,Insulet Corporation, Ypsomed Holdings, Glysens Incorporated

 

Key Market Drivers

Constant monitoring - A continuous monitoring system helps to evaluate the condition of the patient constantly and can be reevaluated for selecting the suitable line of treatment and diet. An increase in the number of diabetes patients which is mostly due to a change in their lifestyles and other environmental factors Will drive the market growth in the coming years period obesity is another reason which leads to diabetes which will in turn increase the need for monitoring devices. The number of deaths that have occurred recently, especially in the United States will lead to the growth of the market during the forecast period. 

Easy application - The process of operating these techniques is extremely easy and comfortable which attracts potential consumers. The availability of devices that are easy to use will also help in the growth of the market. Constant research and development in this field will lead to the introduction of better and more efficient devices in the coming years period as many new products are being launched in the market the users of these products can easily access their products. 

Key Market Challenges

High cost of technology - The expensive devices which are used for the procedure prove to be a major challenge for the key market players. The lack of disposable income available to the people hampers the growth of the market considerably. The development cost of these devices is high and the reimbursement policy is offered in the market are not favorable due to which the market growth will be hampered in the coming years. The supply of these blood glucose monitoring systems is also affected to a great extent. When it comes to the nations like India and China the use of these devices has increased but the high cost of these devices will hamper the growth of the market in the coming years. An increase in the number of expenses made by the consumers for these devices will put a major strain on the consumers especially when it comes to developing nations. In underdeveloped nations, the high cost of these devices will reduce their penetration and prove to be a challenge to enter these markets. 

Key Market Opportunities

Increasing demand for advanced technology - Increasing awareness regarding the available facilities and advanced technologies for monitoring non-invasive blood glucose and controlling it has helped the market of non-invasive blood glucose monitoring systems to show tremendous growth. As many market players are engaged in providing innovative products and the availability of advanced technologies for these products will lead to the growth of the market and provide good opportunities in the coming years.

One of the leading technologies which are being used in this industry is electromagnetism. The availability of these devices in the form of wearable and non-wearable types will also provide good opportunities for the growth of this market. 

Regional Insights

On the basis of geography, the huge number of people who are suffering from diabetes and non-invasive blood glucose disorders in the region of North America has proved to be a major factor that has made this region a dominant market and is foreseen to continue in a similar fashion during the future as well. As a result of the developed status of the country these sedentary lifestyle practices have increased to a great extent which results from the huge number of multinational companies would you demand long working hours. Hence the increasing amount of stress and lifestyle disorders have proved to be the causative factors for diabetes and other non-invasive blood glucose-related disorders. The demand for non-invasive blood glucose monitoring systems has seen a tremendous boost in this region which is supported by the high disposable income available to the people.

The next largest market which follows is the region of Europe which comprises a huge client base suffering from diabetes. The rapidly growing awareness regarding the management of diabetes among people has boosted the market size of non-invasive blood glucose monitoring systems. The region of Asia Pacific has emerged as the next sector which has shown considerable growth due to the increasing number of people suffering from diabetes and hence the demand and supply of non-invasive blood glucose monitoring systems have increased.

Recent Developments

  • In February 2021 – Ascensia diabetes care holding AG acquired the distribution channel of Eversense XL, which is located in Germany, Spain, Italy, Netherlands, and Switzerland with a view to meet the increasing demands in the market of Europe.
  • In March 2021 – F. Hoffmann- la Roche Co Introduced Accuchek instant product which connects directly to with mySugr app. This app provides the data for non-invasive blood glucose parameters in real-time. 

Key Market Players

  • Abbott Laboratories
  • Medtronic plc
  • F. Hoffmann-La Roche Ltd.
  • Ascensia Diabetes Care
  • Dexcom, Inc.
  • Sanofi Novo Nordisk
  • Insulet Corporation
  • Ypsomed Holdings
  • Glysens Incorporated

Segments Covered in the Report

By Technology

  • Spectroscopy 
  • Electromagnetic 
  • Microwave 
  • Ultrasonic 
  • Thermal 
  • Others

By End User

  • Hospitals
  • Homecare
  • Clinics

By Modality

  • Non wearable
  • Wearable
  • Invasive
  • Non-invasive

By Distribution Channel

  • Retail sales
  • Institutional sales
  • By Geography

North America

  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Frequently Asked Questions

The global non-invasive blood glucose monitoring system market size was reached at USD 22.00 billion in 2022 and it is projected to hit around USD 166.05 billion by 2032.

The global non-invasive blood glucose monitoring system market is growing at a compound annual growth rate (CAGR) of 22.4% from 2023 to 2032.

The North America region has accounted for the largest Non-Invasive Blood Glucose Monitoring System market share in 2022.

Abbott Laboratories ,Medtronic plc, F. Hoffmann-La Roche Ltd., Ascensia Diabetes Care ,Dexcom, Inc., Sanofi Novo Nordisk ,Insulet Corporation, Ypsomed Holdings, Glysens Incorporated

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Non-Invasive Blood Glucose Monitoring System Market 

5.1. COVID-19 Landscape: Non-Invasive Blood Glucose Monitoring System Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Non-Invasive Blood Glucose Monitoring System Market, By Technology

8.1. Non-Invasive Blood Glucose Monitoring System Market, by Technology, 2023-2032

8.1.1. Spectroscopy

8.1.1.1. Market Revenue and Forecast (2021-2032)

8.1.2. Electromagnetic

8.1.2.1. Market Revenue and Forecast (2021-2032)

8.1.3. Microwave

8.1.3.1. Market Revenue and Forecast (2021-2032)

8.1.4. Ultrasonic

8.1.4.1. Market Revenue and Forecast (2021-2032)

8.1.5. Thermal

8.1.5.1. Market Revenue and Forecast (2021-2032)

8.1.6. Others

8.1.6.1. Market Revenue and Forecast (2021-2032)

Chapter 9. Global Non-Invasive Blood Glucose Monitoring System Market, By End User

9.1. Non-Invasive Blood Glucose Monitoring System Market, by End User, 2023-2032

9.1.1. Others

9.1.1.1. Market Revenue and Forecast (2021-2032)

9.1.2. Homecare

9.1.2.1. Market Revenue and Forecast (2021-2032)

9.1.3. Homecare

9.1.3.1. Market Revenue and Forecast (2021-2032)

Chapter 10. Global Non-Invasive Blood Glucose Monitoring System Market, By Modality 

10.1. Non-Invasive Blood Glucose Monitoring System Market, by Modality, 2023-2032

10.1.1. Homecare

10.1.1.1. Market Revenue and Forecast (2021-2032)

10.1.2. Homecare

10.1.2.1. Market Revenue and Forecast (2021-2032)

10.1.3. Invasive

10.1.3.1. Market Revenue and Forecast (2021-2032)

10.1.4. Non-invasive

10.1.4.1. Market Revenue and Forecast (2021-2032)

Chapter 11. Global Non-Invasive Blood Glucose Monitoring System Market, By Distribution Channel 

11.1. Non-Invasive Blood Glucose Monitoring System Market, by Distribution Channel, 2023-2032

11.1.1. Retail sales

11.1.1.1. Market Revenue and Forecast (2021-2032)

11.1.2. Institutional sales

11.1.2.1. Market Revenue and Forecast (2021-2032)

Chapter 12. Global Non-Invasive Blood Glucose Monitoring System Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Technology (2021-2032)

12.1.2. Market Revenue and Forecast, by End User (2021-2032)

12.1.3. Market Revenue and Forecast, by Modality (2021-2032)

12.1.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Technology (2021-2032)

12.1.5.2. Market Revenue and Forecast, by End User (2021-2032)

12.1.5.3. Market Revenue and Forecast, by Modality (2021-2032)

12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Technology (2021-2032)

12.1.6.2. Market Revenue and Forecast, by End User (2021-2032)

12.1.6.3. Market Revenue and Forecast, by Modality (2021-2032)

12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Technology (2021-2032)

12.2.2. Market Revenue and Forecast, by End User (2021-2032)

12.2.3. Market Revenue and Forecast, by Modality (2021-2032)

12.2.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Technology (2021-2032)

12.2.5.2. Market Revenue and Forecast, by End User (2021-2032)

12.2.5.3. Market Revenue and Forecast, by Modality (2021-2032)

12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Technology (2021-2032)

12.2.6.2. Market Revenue and Forecast, by End User (2021-2032)

12.2.6.3. Market Revenue and Forecast, by Modality (2021-2032)

12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Technology (2021-2032)

12.2.7.2. Market Revenue and Forecast, by End User (2021-2032)

12.2.7.3. Market Revenue and Forecast, by Modality (2021-2032)

12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Technology (2021-2032)

12.2.8.2. Market Revenue and Forecast, by End User (2021-2032)

12.2.8.3. Market Revenue and Forecast, by Modality (2021-2032)

12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Technology (2021-2032)

12.3.2. Market Revenue and Forecast, by End User (2021-2032)

12.3.3. Market Revenue and Forecast, by Modality (2021-2032)

12.3.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Technology (2021-2032)

12.3.5.2. Market Revenue and Forecast, by End User (2021-2032)

12.3.5.3. Market Revenue and Forecast, by Modality (2021-2032)

12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Technology (2021-2032)

12.3.6.2. Market Revenue and Forecast, by End User (2021-2032)

12.3.6.3. Market Revenue and Forecast, by Modality (2021-2032)

12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Technology (2021-2032)

12.3.7.2. Market Revenue and Forecast, by End User (2021-2032)

12.3.7.3. Market Revenue and Forecast, by Modality (2021-2032)

12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Technology (2021-2032)

12.3.8.2. Market Revenue and Forecast, by End User (2021-2032)

12.3.8.3. Market Revenue and Forecast, by Modality (2021-2032)

12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Technology (2021-2032)

12.4.2. Market Revenue and Forecast, by End User (2021-2032)

12.4.3. Market Revenue and Forecast, by Modality (2021-2032)

12.4.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Technology (2021-2032)

12.4.5.2. Market Revenue and Forecast, by End User (2021-2032)

12.4.5.3. Market Revenue and Forecast, by Modality (2021-2032)

12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Technology (2021-2032)

12.4.6.2. Market Revenue and Forecast, by End User (2021-2032)

12.4.6.3. Market Revenue and Forecast, by Modality (2021-2032)

12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Technology (2021-2032)

12.4.7.2. Market Revenue and Forecast, by End User (2021-2032)

12.4.7.3. Market Revenue and Forecast, by Modality (2021-2032)

12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Technology (2021-2032)

12.4.8.2. Market Revenue and Forecast, by End User (2021-2032)

12.4.8.3. Market Revenue and Forecast, by Modality (2021-2032)

12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Technology (2021-2032)

12.5.2. Market Revenue and Forecast, by End User (2021-2032)

12.5.3. Market Revenue and Forecast, by Modality (2021-2032)

12.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Technology (2021-2032)

12.5.5.2. Market Revenue and Forecast, by End User (2021-2032)

12.5.5.3. Market Revenue and Forecast, by Modality (2021-2032)

12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Technology (2021-2032)

12.5.6.2. Market Revenue and Forecast, by End User (2021-2032)

12.5.6.3. Market Revenue and Forecast, by Modality (2021-2032)

12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

Chapter 13. Company Profiles

13.1. Abbott Laboratories

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Medtronic plc

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. F. Hoffmann-La Roche Ltd.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Ascensia Diabetes Care

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Dexcom, Inc.

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Sanofi Novo Nordisk

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Abbott

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Ypsomed Holdings

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Glysens Incorporated

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers